MX2022009732A - Composiciones de heparina de alto peso molecular y metodos para diagnosticar, tratar y monitorear enfermedades inflamatorias mediadas por eosinofilos. - Google Patents

Composiciones de heparina de alto peso molecular y metodos para diagnosticar, tratar y monitorear enfermedades inflamatorias mediadas por eosinofilos.

Info

Publication number
MX2022009732A
MX2022009732A MX2022009732A MX2022009732A MX2022009732A MX 2022009732 A MX2022009732 A MX 2022009732A MX 2022009732 A MX2022009732 A MX 2022009732A MX 2022009732 A MX2022009732 A MX 2022009732A MX 2022009732 A MX2022009732 A MX 2022009732A
Authority
MX
Mexico
Prior art keywords
molecular weight
high molecular
methods
weight heparin
treating
Prior art date
Application number
MX2022009732A
Other languages
English (en)
Inventor
Gerald J Gleich
Russell Morris Condie
Kristin M Leiferman
Kathryn A Peterson
Debra Eckert
Hedieh Saffari
Original Assignee
Univ Utah Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah Res Found filed Critical Univ Utah Res Found
Publication of MX2022009732A publication Critical patent/MX2022009732A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
    • A61B6/40—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment with arrangements for generating radiation specially adapted for radiation diagnosis
    • A61B6/4057—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment with arrangements for generating radiation specially adapted for radiation diagnosis by using radiation sources located in the interior of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases

Abstract

En la presente descripción se describen composiciones que comprenden heparina de alto peso molecular. Las composiciones comprenden una cantidad efectiva de heparina de alto peso molecular que tiene un peso molecular promedio de aproximadamente 20 kDa a aproximadamente 40 kDa y que tiene una pureza de al menos el 50 %, y un excipiente farmacéuticamente aceptable. En la presente descripción se describen también métodos para tratar la inflamación relacionada con eosinófilos en un sujeto.
MX2022009732A 2020-02-10 2021-02-10 Composiciones de heparina de alto peso molecular y metodos para diagnosticar, tratar y monitorear enfermedades inflamatorias mediadas por eosinofilos. MX2022009732A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062972224P 2020-02-10 2020-02-10
PCT/US2021/017453 WO2021163190A1 (en) 2020-02-10 2021-02-10 High molecular weight heparin compositions and methods for diagnosing, treating and monitoring eosinophil mediated inflammatory diseases

Publications (1)

Publication Number Publication Date
MX2022009732A true MX2022009732A (es) 2022-09-09

Family

ID=77292607

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009732A MX2022009732A (es) 2020-02-10 2021-02-10 Composiciones de heparina de alto peso molecular y metodos para diagnosticar, tratar y monitorear enfermedades inflamatorias mediadas por eosinofilos.

Country Status (11)

Country Link
US (1) US20230346990A1 (es)
EP (1) EP4103196A1 (es)
JP (1) JP2023513548A (es)
KR (1) KR20220143016A (es)
CN (1) CN116096375A (es)
AU (1) AU2021221108A1 (es)
BR (1) BR112022015843A2 (es)
CA (1) CA3167606A1 (es)
IL (1) IL295232A (es)
MX (1) MX2022009732A (es)
WO (1) WO2021163190A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4326782A1 (en) 2021-05-12 2024-02-28 Nexeos Diagnostics, Inc. Methods of manufacturing a high molecular weight heparin compound

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
US20130150323A1 (en) * 2010-02-04 2013-06-13 Urigen Pharmaceuticals, Inc Use of oral heparin preparations to treat urinary tract diseases and conditions
WO2013120497A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013173716A2 (en) * 2012-05-18 2013-11-21 University Of Utah Research Foundation Methods for diagnosing and monitoring eosinophilic esophagitis

Also Published As

Publication number Publication date
CN116096375A (zh) 2023-05-09
CA3167606A1 (en) 2021-08-19
IL295232A (en) 2022-10-01
AU2021221108A1 (en) 2022-09-29
US20230346990A1 (en) 2023-11-02
BR112022015843A2 (pt) 2022-09-27
EP4103196A1 (en) 2022-12-21
WO2021163190A1 (en) 2021-08-19
JP2023513548A (ja) 2023-03-31
KR20220143016A (ko) 2022-10-24
WO2021163190A4 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
MX2022009732A (es) Composiciones de heparina de alto peso molecular y metodos para diagnosticar, tratar y monitorear enfermedades inflamatorias mediadas por eosinofilos.
DK1283735T3 (da) Fremgangsmåde til fremstilling af hydrazon-derivater
BR0209922A (pt) Método para tratar uma condição médica que envolve a angiogênese em um paciente, para inibir a vascularização de células endoteliais, e para tratar câncer em um mamìfero
GB2554296A (en) Antithrombin-heparin compositions and methods
JP2009510091A5 (es)
NO934319L (no) Fremgangsmaater og sammensetninger basert paa hemming av celleinvas jon og fibrose ved anioniske polymerer
UA92603C2 (ru) Фармацевтическая композиция для лечения тромбоза
MX2021000861A (es) Fucanos de alto peso molecular para tratar adhesiones fibrosas y otras enfermedades y padecimientos.
EP1567117A4 (en) MATERIALS AND METHODS FOR THE PREVENTION AND TREATMENT OF EPITHELIAL DISORDERS WITH MICROBIAL MEDIATION
WO2022173888A8 (en) Pharmaceutically acceptable salts of psilocin and uses thereof
MX2020013275A (es) Nuevos compuestos y sus composiciones farmaceuticas para el tratamiento de enfermedades.
KR101763440B1 (ko) 과황산화 이당 제제
PH12019502764A1 (en) Compounds and compositions for inducing chondrogenesis
MX2022009544A (es) Composicion para prevenir o tratar enfermedades pulmonares que comprende proteina 1 de union de hialuronano y proteoglucano.
WO2021191689A3 (en) Treatment of inflammatory diseases with peptides and pharmaceutical compositions
JP2009096807A (ja) アレルギー性疾患の予防または治療薬
WO2021097434A8 (en) Fibroblast therapy for inflammatory bowel disease
MX2021011575A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
EP4321216A3 (en) Compositions and methods for treating inflammatory neurological disorders
WO2022034158A3 (en) Compositions and methods for the treatment of diseases by enhancing arginase 2 in macrophages
WO2023114945A3 (en) Vandetanib reduces inflammatory cytokines and ameliorates covid-19
EP2893926B1 (en) Composition and method for the protection of articular cartilage
WO2003076602A3 (fr) Siomerieux s.a. - inserm
WO2024023585A3 (en) Urolithin and fluorene derivatives for inhibiting ferroptosis
MX2022010645A (es) Composiciones topicas dise?adas para mantener y/o restaurar la integridad de la mucosa y epidermis da?ada.